Real-world experience with lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617) in metastatic castration resistant prostate cancer (mCRPC): Results from the interim analysis of an observational, multicenter, prospective cohort study complemented by German healthcare data (DGU 2026) - Oct 15, 2026 - Abstract #V21-04; Pres time: Sep 17, 2026; 01:30 PM - 01:40 PM; Location: Room 28; "This interim analysis provides insights into the clinical characteristics, treatment patterns, and HRQoL of patients with mCRPC receiving 177 Lu-PSMA-617 in routine practice in Germany. Further data from the follow-up period will be essential to evaluate changes in HRQoL over time. Copyright : Abstract to be presented at DGN 2026 for the target group of nuclear medicine specialists."
Clinical • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
C. la Fougère 1; M. Essler 2; M. Starke 3; E. Aßmann 4; A. Buck 5
|